Fruquintinib Hydrochloride 1 mg, 5 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 1 mg, 5 mg
Reference Brands: Fruzaqla (USA/EU), Elunate (USA/EU)
Category: Oncology Cancer Care
Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor used for the treatment of metastatic colorectal cancer. It works by selectively blocking VEGFR-1, VEGFR-2, and VEGFR-3, thereby inhibiting tumor angiogenesis and slowing cancer growth.
Fruquintinib Hydrochloride — third party manufacturing & bulk supply
Fruquintinib Hydrochloride 1 mg, 5 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Fruquintinib Hydrochloride is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Fruquintinib Hydrochloride listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Fruquintinib Hydrochloride →Frequently Asked Questions
Fruquintinib hydrochloride is used to treat adults with metastatic colorectal cancer who have been previously treated with chemotherapy and other targeted therapies.
Fruquintinib hydrochloride is made from the active ingredient Fruquintinib, a selective VEGFR inhibitor, combined with hydrochloride to form a stable salt for oral use.
The trade name of Fruquintinib hydrochloride is Fruzaqla and Elunate.
Fruquintinib hydrochloride is developed and manufactured by Hutchmed and licensed to Takeda Pharmaceuticals for global distribution.
The generic name is Fruquintinib hydrochloride.
Brand names include Fruzaqla and Elunate.
Fruquintinib hydrochloride is manufactured in China, Japan, and the United States by Hutchmed and Takeda Pharmaceuticals for international oncology markets.
Related Products
Tivozanib Hydrochloride
Strength:
0.89 mg, 1.34 mg
Form: Capsules
Reference Brands: Fotivda (USA/EU)
View Details
Degarelix Acetate
Strength:
120 mg/vial, 80 mg/vial
Form: Injection
Reference Brands: Firmagon (USA, EU)
View Details
Obinutuzumab
Strength:
25 mg/mL
Form: Injection
Reference Brands: Gazyva (USA), Gazyvaro (EU/UK)
View Details
Essential Trace Minerals With Lycopene Tablets
Strength:
30gm
Form: tablets
Reference Brands:
View DetailsQuick Response Guaranteed | Verified Suppliers
